another modality for treating breast cancer liver mets

[Lani]

Radiother Oncol. 2011 Apr 15. [Epub ahead of print]
Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy - A phase II-study.
Wieners G, Mohnike K, Peters N, Bischoff J, Kleine-Tebbe A, Seidensticker R, Seidensticker M, Gademann G, Wust P, Pech M, Ricke J.

Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke-University Magdeburg, Germany.
Abstract
PURPOSE: The aim of the study was the evaluation of feasibility, safety and effectiveness of interstitial brachytherapy for the treatment of hepatic metastases of breast cancer.

MATERIALS AND METHODS: Forty-one consecutive patients with 115 unresectable hepatic metastases of breast cancer were included in this phase-II-trial. They were treated in 69 interventions of CT-guided-interstitial-brachytherapy of the liver. Brachytherapy was applied as a single fraction high-dose-irradiation (15-25Gy (Gray)) using a (192)Ir-source of 10Ci. Nineteen patients presented systemically pretreated extrahepatic tumors. Primary endpoints were complications, local tumor control and progression-free survival.

RESULTS: The median tumor diameter was 4.6cm (1.5-11cm). The median irradiation time per intervention was 26.5min (range: 7-47min). The applied median minimal dose at the CTV (clinical target volume) margin was 18.5Gy (12-25Gy). In 69 interventions and during the postinterventional period, one major complication (symptomatic post-interventional bleeding) (1.5%) and six minor complications occurred (8.7%). The median follow-up time was 18months (range: 1-56). After 6, 12 and 18months, local tumor control was 97%, 93.5% and 93.5%, intra- and extrahepatic progression free survival was 53%, 40% and 27%, and overall survival was 97%, 79% and 60%, respectively.

CONCLUSION: CT-guided-brachytherapy is safe and effective for the treatment of liver metastases of breast cancer.

Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
PMID: 21497930